Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.75 EUR
Change Today +0.105 / 3.98%
Volume 0.0
As of 2:16 AM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

solazyme inc (S7Y) Snapshot

Open
€2.75
Previous Close
€2.64
Day High
€2.79
Day Low
€2.75
52 Week High
06/18/14 - €9.04
52 Week Low
02/26/15 - €1.49
Market Cap
219.8M
Average Volume 10 Days
214.9
EPS TTM
--
Shares Outstanding
80.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SOLAZYME INC (S7Y)

solazyme inc (S7Y) Related Businessweek News

View More BusinessWeek News

solazyme inc (S7Y) Details

Solazyme, Inc. manufactures and sells renewable oils and other bioproducts. Its proprietary technology transforms a range of plant-based sugars into triglyceride oils and other bioproducts. The company offers renewable tailored oils, such as oleic oils that provide sustainable solutions within the food, lubricant, functional fluid, and oleo chemical markets; and drop-in replacements and blendstocks for marine, motor vehicle, and jet fuels, as well as replacements for petrochemicals, oleochemicals, and functional fluids. It also provides fuels, including SoladieselBD and SoladieselRD for on-road applications; ultra-low sulfur diesel; and Solajet for aviation use. In addition, the company offers microalgae-based food ingredients consisting of Tailored oils and powdered oils; and powdered ingredients comprising AlgaVia whole algal flour, AlgaVia whole algal protein, AlgaVia lipid powder, and encapsulated oils. Additionally, it provides skin and personal care products under the Algenist brand name, which include concentrated reconstructing serum, an anti-aging serum; complete eye renewal balm; firming and lifting cream, an anti-aging moisturizing cream; advanced anti-aging repairing oil, a face oil formulation; and genius cream. The company was incorporated in 2003 and is headquartered in South San Francisco, California.

266 Employees
Last Reported Date: 03/6/15
Founded in 2003

solazyme inc (S7Y) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $560.0K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: $410.4K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $335.0K
Chief Technology Officer
Total Annual Compensation: $370.8K
Strategic Advisor
Total Annual Compensation: $378.8K
Compensation as of Fiscal Year 2014.

solazyme inc (S7Y) Key Developments

Solazyme, Inc. Presents at Morgan Stanley MLP/Diversified Natural Gas, Utilities and Clean Tech Conference, Mar-05-2015

Solazyme, Inc. Presents at Morgan Stanley MLP/Diversified Natural Gas, Utilities and Clean Tech Conference, Mar-05-2015 . Venue: The St. Regis, New York, New York, United States. Speakers: Tyler W. Painter, Chief Financial Officer, Chief Operating Officer and Principal Accounting Officer.

Solazyme, Inc. announced delayed annual 10-K filing

On 03/02/2015, Solazyme, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Solazyme, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Solazyme, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. Total revenue was $14,502,000 compared to $11,274,000 a year ago. Loss from operations was $35,515,000 compared to $28,015,000 a year ago. Net loss was $44,866,000 or $0.57 per basic and diluted share compared to $33,336,000 or $0.49 per basic and diluted share a year ago. Net loss (non-GAAP) was $35,470,000 or $0.45 per share compared to $27,420,000 or $0.40 per share a year ago. For the full year, the company reported total revenues of $60,391,000 compared to $39,750,000 a year ago. Loss from operations was $135,681,000 compared to $96,140,000 a year ago. Net loss was $162,141,000 or $2.14 per basic and diluted share compared to $116,389,000 or $1.81 per basic and diluted share a year ago. Net loss (non-GAAP) was $133,351,000 or $1.76 per share compared to $88,556,000 or $1.38 per share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
S7Y:GR €2.75 EUR +0.105

S7Y Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amyris Inc $2.36 USD +0.09
Gevo Inc $0.21 USD -0.0376
Wessanen €6.25 EUR 0.00
Pacific Ethanol Inc $10.65 USD +0.31
View Industry Companies
 

Industry Analysis

S7Y

Industry Average

Valuation S7Y Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.7x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SOLAZYME INC, please visit www.solazyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.